Adaptimmune Therapeutics PLC Insider Trading for March 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptimmune Therapeutics PLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Adaptimmune Therapeutics PLC for March 2018.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 29 2018 | ADAP | Adaptimmune Therap ... | Thompson Peter A. | Director | Sell | S | 11.53 | 31,983 | 368,764 | 5,101,310 | 5.1 M to 5.1 M (-0.62 %) |
Mar 29 2018 | ADAP | Adaptimmune Therap ... | Thompson Peter A. | Director | Sell | S | 11.50 | 1,016,084 | 11,684,966 | 5,133,293 | 6.1 M to 5.1 M (-16.52 %) |
Mar 29 2018 | ADAP | Adaptimmune Therap ... | ORBIMED ADVISORS LLC | Director | Sell | S | 11.53 | 31,983 | 368,764 | 5,101,310 | 5.1 M to 5.1 M (-0.62 %) |
Mar 29 2018 | ADAP | Adaptimmune Therap ... | ORBIMED ADVISORS LLC | Director | Sell | S | 11.50 | 1,016,084 | 11,684,966 | 5,133,293 | 6.1 M to 5.1 M (-16.52 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | Viswanathan Ravi | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | Viswanathan Ravi | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | KERINS PATRICK J | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | KERINS PATRICK J | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | BARRIS PETER J | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | BARRIS PETER J | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | BARRETT M JAMES | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | BARRETT M JAMES | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Viswanathan Ravi | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Viswanathan Ravi | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Viswanathan Ravi | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Sonsini Peter W. | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | SANDELL SCOTT D | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | KERINS PATRICK J | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | KERINS PATRICK J | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | KERINS PATRICK J | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | Florence Anthony A. Jr. | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BASKETT FOREST | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BARRIS PETER J | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BARRIS PETER J | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BARRIS PETER J | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BARRETT M JAMES | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BARRETT M JAMES | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | BARRETT M JAMES | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
Mar 23 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
Mar 22 2018 | ADAP | Adaptimmune Therap ... | Rawcliffe Adrian | Chief Financial Off ... | Sell | S | 1.71 | 600,000 | 1,026,000 | 0 | 600 K to 0 (-100.00 %) |